1. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.;Antman;J Clin Oncol,1997
2. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial.;Bergh;Lancet,2000
3. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC MA-13.;Peters;Proc Am Soc Clin Oncol,2001
4. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with > 3 positive nodes (LN+).;Gianni;Proc Am Soc Clin Oncol,2001
5. High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer and 4 or more involved axillary lymph nodes (4+ LN): The Anglo-Celtic I study.;Crown;Proc Am Soc Clin Oncol,2002